Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinoma.

Cocks M, Chaux A, Jenson EG, Miller JA, Rodriguez Pena MDC, Tregnago AC, Taheri D, Eich ML, Sharma R, Vang R, Netto GJ.

Virchows Arch. 2020 Jan 28. doi: 10.1007/s00428-020-02759-y. [Epub ahead of print]

PMID:
31993774
2.

Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: A nationwide study.

Hannibal CG, Frederiksen K, Vang R, Kurman RJ, Kjaer SK.

Int J Cancer. 2020 Jan 12. doi: 10.1002/ijc.32864. [Epub ahead of print]

PMID:
31930502
3.

BRAFV600E -mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma.

Chui MH, Kjaer SK, Frederiksen K, Hannibal CG, Wang TL, Vang R, Shih IM.

Oncotarget. 2019 Dec 3;10(64):6870-6878. doi: 10.18632/oncotarget.27326. eCollection 2019 Dec 3.

4.

Ovarian Intermediate Trophoblastic Tumors: Genotyping Defines a Distinct Category of Nongestational Tumors of Germ Cell Type.

Xing D, Zhong M, Ye F, O'Malley MT, Li S, Vang R, Ronnett BM.

Am J Surg Pathol. 2019 Nov 1. doi: 10.1097/PAS.0000000000001402. [Epub ahead of print]

PMID:
31688005
5.

Prevalence of somatic and germline mutations of Fumarate hydratase in uterine leiomyomas from young patients.

Liu C, Dillon J, Beavis AL, Liu Y, Lombardo K, Fader AN, Hung CF, Wu TC, Vang R, Garcia JE, Xing D.

Histopathology. 2020 Feb;76(3):354-365. doi: 10.1111/his.14007. Epub 2020 Jan 13.

PMID:
31564060
6.

Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.

Xing D, Liu Y, Park HJ, Baek I, Tran H, Cheang G, Novo J, Dillon J, Matoso A, Farmer E, Cheng MA, Tsai YC, Lombardo K, Conner MG, Vang R, Hung CF, Wu TC, Song W.

Hum Pathol. 2019 Oct;92:67-80. doi: 10.1016/j.humpath.2019.08.003. Epub 2019 Aug 19.

PMID:
31437519
7.

Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.

Chui MH, Xing D, Zeppernick F, Wang ZQ, Hannibal CG, Frederiksen K, Kjaer SK, Cope L, Kurman RJ, Shih IM, Wang TL, Vang R.

Am J Surg Pathol. 2019 Nov;43(11):1462-1472. doi: 10.1097/PAS.0000000000001325.

PMID:
31343420
8.

Lineage-Specific Alterations in Gynecologic Neoplasms with Choriocarcinomatous Differentiation: Implications for Origin and Therapeutics.

Xing D, Zheng G, Pallavajjala A, Schoolmeester JK, Liu Y, Haley L, Hu Y, Liu L, Logan L, Lin Y, Pearce KE, Sattler CA, Tsai YC, Vang R, Hung CF, Wu TC, Ronnett BM.

Clin Cancer Res. 2019 Jul 15;25(14):4516-4529. doi: 10.1158/1078-0432.CCR-18-4278. Epub 2019 Apr 22.

PMID:
31010836
9.

Cytomorphologic and molecular analyses of fallopian tube fimbrial brushings for diagnosis of serous tubal intraepithelial carcinoma.

Chui MH, Vang R, Wang TL, Shih IM, VandenBussche CJ.

Cancer Cytopathol. 2019 Mar;127(3):192-201. doi: 10.1002/cncy.22110. Epub 2019 Mar 12.

PMID:
30861338
10.

Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions.

Wu RC, Wang P, Lin SF, Zhang M, Song Q, Chu T, Wang BG, Kurman RJ, Vang R, Kinzler K, Tomasetti C, Jiao Y, Shih IM, Wang TL.

J Pathol. 2019 May;248(1):41-50. doi: 10.1002/path.5219. Epub 2019 Feb 15.

11.
12.

Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.

Aggarwal C, Cohen RB, Morrow MP, Kraynyak KA, Sylvester AJ, Knoblock DM, Bauml JM, Weinstein GS, Lin A, Boyer J, Sakata L, Tan S, Anton A, Dickerson K, Mangrolia D, Vang R, Dallas M, Oyola S, Duff S, Esser M, Kumar R, Weiner D, Csiki I, Bagarazzi ML.

Clin Cancer Res. 2019 Jan 1;25(1):110-124. doi: 10.1158/1078-0432.CCR-18-1763. Epub 2018 Sep 21.

13.

Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.

Visvanathan K, Shaw P, May BJ, Bahadirli-Talbott A, Kaushiva A, Risch H, Narod S, Wang TL, Parkash V, Vang R, Levine DA, Soslow R, Kurman R, Shih IM.

Cancer Prev Res (Phila). 2018 Nov;11(11):697-706. doi: 10.1158/1940-6207.CAPR-18-0009. Epub 2018 Sep 19.

14.

An Epithelioid Smooth Muscle Neoplasm Mimicking a Signet Ring Cell Carcinoma in the Ovary.

Xing D, Berrebi AA, Liu C, Richmond A, Vang R, Ronnett BM.

Int J Gynecol Pathol. 2019 Sep;38(5):464-469. doi: 10.1097/PGP.0000000000000520.

PMID:
29750703
15.

Clinicopathologic Features and Genetic Alterations of a Primary Osteosarcoma of the Uterine Corpus.

Zheng G, Richmond A, Liu C, Berrebi A, Pallavajjala A, Haley L, Stone RL, McCarthy E, Vang R, Xing D.

Int J Gynecol Pathol. 2019 Sep;38(5):414-419. doi: 10.1097/PGP.0000000000000511.

PMID:
29629977
16.

Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix.

Xing D, Zheng G, Schoolmeester JK, Li Z, Pallavajjala A, Haley L, Conner MG, Vang R, Hung CF, Wu TC, Ronnett BM.

Am J Surg Pathol. 2018 Jun;42(6):750-760. doi: 10.1097/PAS.0000000000001042.

17.

Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study.

Xing D, Banet N, Sharma R, Vang R, Ronnett BM, Illei PB.

Hum Pathol. 2018 Feb;72:160-166. doi: 10.1016/j.humpath.2017.10.036. Epub 2017 Dec 11.

PMID:
29241740
18.

Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy.

Morrow MP, Kraynyak KA, Sylvester AJ, Dallas M, Knoblock D, Boyer JD, Yan J, Vang R, Khan AS, Humeau L, Sardesai NY, Kim JJ, Plotkin S, Weiner DB, Trimble CL, Bagarazzi ML.

Clin Cancer Res. 2018 Jan 15;24(2):276-294. doi: 10.1158/1078-0432.CCR-17-2335. Epub 2017 Oct 30.

19.

Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.

Xing D, Suryo Rahmanto Y, Zeppernick F, Hannibal CG, Kjaer SK, Vang R, Shih IM, Wang TL.

Hum Pathol. 2017 Oct;68:87-91. doi: 10.1016/j.humpath.2017.08.021. Epub 2017 Sep 2.

20.

The Utility of Sentinel Lymph Node Mapping in High-Grade Endometrial Cancer.

Tanner EJ, Ojalvo L, Stone RL, Levinson K, Temkin SM, Murdock T, Vang R, Sinno AK, Fader AN.

Int J Gynecol Cancer. 2017 Sep;27(7):1416-1421. doi: 10.1097/IGC.0000000000001047.

PMID:
30814241
21.

Performance test and verification of an off-the-shelf automated avian radar tracking system.

May R, Steinheim Y, Kvaløy P, Vang R, Hanssen F.

Ecol Evol. 2017 Jun 22;7(15):5930-5938. doi: 10.1002/ece3.3162. eCollection 2017 Aug.

22.

Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.

Vang R, Hannibal CG, Junge J, Frederiksen K, Kjaer SK, Kurman RJ.

Am J Surg Pathol. 2017 Jun;41(6):725-737. doi: 10.1097/PAS.0000000000000824.

23.

Interobserver Reproducibility Among Gynecologic Pathologists in Diagnosing Heterologous Osteosarcomatous Component in Gynecologic Tract Carcinosarcomas.

Sangoi AR, Kshirsagar M, Roma AA, Horvai AE, Chivukula M, Ellenson LH, Fadare O, Folkins AK, Garg K, Hanley K, Longacre TA, Haas J, McCluggage WG, McKenney JK, Nucci MR, Oliva E, Park KJ, Parkash V, Quick CM, Rabban JT, Rutgers JKL, Soslow R, Vang R, Yemelyanova A, Zaloudek C, Beck AH.

Int J Gynecol Pathol. 2017 Jul;36(4):386-392. doi: 10.1097/PGP.0000000000000329.

PMID:
28221217
24.

Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study.

Rasmussen ELK, Hannibal CG, Dehlendorff C, Baandrup L, Junge J, Vang R, Kurman RJ, Kjaer SK.

Gynecol Oncol. 2017 Mar;144(3):571-576. doi: 10.1016/j.ygyno.2017.01.002. Epub 2017 Jan 17.

PMID:
28108026
25.

A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.

Hannibal CG, Vang R, Junge J, Frederiksen K, Kurman RJ, Kjaer SK.

Gynecol Oncol. 2017 Jan;144(1):174-180. doi: 10.1016/j.ygyno.2016.11.007. Epub 2016 Nov 9.

26.

Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system.

Voltaggio L, Cimino-Mathews A, Bishop JA, Argani P, Cuda JD, Epstein JI, Hruban RH, Netto GJ, Stoler MH, Taube JM, Vang R, Westra WH, Montgomery EA.

CA Cancer J Clin. 2016 Sep;66(5):408-36. doi: 10.3322/caac.21350. Epub 2016 Jun 6. Review.

27.

Incidental Serous Tubal Intraepithelial Carcinoma and Non-Neoplastic Conditions of the Fallopian Tubes in Grossly Normal Adnexa: A Clinicopathologic Study of 388 Completely Embedded Cases.

Seidman JD, Krishnan J, Yemelyanova A, Vang R.

Int J Gynecol Pathol. 2016 Sep;35(5):423-9. doi: 10.1097/PGP.0000000000000267.

PMID:
26630221
28.

Invasive Complete Hydatidiform Moles: Analysis of a Case Series With Genotyping.

Bynum J, Murphy KM, DeScipio C, Beierl K, Adams E, Anderson D, Vang R, Ronnett BM.

Int J Gynecol Pathol. 2016 Mar;35(2):134-41. doi: 10.1097/PGP.0000000000000232.

PMID:
26535984
29.

Carcinoma of the Uterine Cervix Involving the Genitourinary Tract: A Potential Diagnostic Dilemma.

Schwartz LE, Khani F, Bishop JA, Vang R, Epstein JI.

Am J Surg Pathol. 2016 Jan;40(1):27-35. doi: 10.1097/PAS.0000000000000524.

PMID:
26426382
30.

Molecular analysis of ovarian mucinous carcinoma reveals different cell of origins.

Wang Y, Schwartz LE, Anderson D, Lin MT, Haley L, Wu RC, Vang R, Shih IeM, Kurman RJ.

Oncotarget. 2015 Sep 8;6(26):22949-58.

31.

Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.

Vang R, Levine DA, Soslow RA, Zaloudek C, Shih IeM, Kurman RJ.

Int J Gynecol Pathol. 2016 Jan;35(1):48-55. doi: 10.1097/PGP.0000000000000207.

32.

Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).

McCluggage WG, Judge MJ, Clarke BA, Davidson B, Gilks CB, Hollema H, Ledermann JA, Matias-Guiu X, Mikami Y, Stewart CJ, Vang R, Hirschowitz L; International Collaboration on Cancer Reporting.

Mod Pathol. 2015 Aug;28(8):1101-22. doi: 10.1038/modpathol.2015.77. Epub 2015 Jun 19. Review.

33.

Distribution and case-fatality ratios by cell-type for ovarian carcinomas: a 22-year series of 562 patients with uniform current histological classification.

Seidman JD, Vang R, Ronnett BM, Yemelyanova A, Cosin JA.

Gynecol Oncol. 2015 Feb;136(2):336-40. doi: 10.1016/j.ygyno.2014.12.018. Epub 2014 Dec 17.

PMID:
25528497
34.

Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series.

Morrison JC, Blanco LZ Jr, Vang R, Ronnett BM.

Am J Surg Pathol. 2015 Apr;39(4):442-53. doi: 10.1097/PAS.0000000000000352.

PMID:
25517955
35.

GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility.

Banet N, Gown AM, Shih IeM, Kay Li Q, Roden RB, Nucci MR, Cheng L, Przybycin CG, Nasseri-Nik N, Wu LS, Netto GJ, Ronnett BM, Vang R.

Am J Surg Pathol. 2015 Jan;39(1):101-8. doi: 10.1097/PAS.0000000000000315.

36.

BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors.

Zeppernick F, Ardighieri L, Hannibal CG, Vang R, Junge J, Kjaer SK, Zhang R, Kurman RJ, Shih IeM.

Am J Surg Pathol. 2014 Dec;38(12):1603-11. doi: 10.1097/PAS.0000000000000313. Erratum in: Am J Surg Pathol. 2015 Jul;39(7):1014.

37.

PAX8 expression in uterine adenocarcinomas and mesonephric proliferations.

Yemelyanova A, Gown AM, Wu LS, Holmes BJ, Ronnett BM, Vang R.

Int J Gynecol Pathol. 2014 Sep;33(5):492-9. doi: 10.1097/PGP.0b013e3182a54afa.

PMID:
25083965
38.

A subset of malignant phyllodes tumors express p63 and p40: a diagnostic pitfall in breast core needle biopsies.

Cimino-Mathews A, Sharma R, Illei PB, Vang R, Argani P.

Am J Surg Pathol. 2014 Dec;38(12):1689-96. doi: 10.1097/PAS.0000000000000301.

39.

A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population.

Hannibal CG, Vang R, Junge J, Frederiksen K, Kjaerbye-Thygesen A, Andersen KK, Tabor A, Kurman RJ, Kjaer SK.

Gynecol Oncol. 2014 Aug;134(2):267-73. doi: 10.1016/j.ygyno.2014.06.002. Epub 2014 Jun 10.

40.

A subset of nondescript axillary lymph node inclusions have the immunophenotype of endosalpingiosis.

Carney E, Cimino-Mathews A, Argani C, Kronz J, Vang R, Argani P.

Am J Surg Pathol. 2014 Dec;38(12):1612-7. doi: 10.1097/PAS.0000000000000261.

41.

PAX8 expression in uterine malignant mesodermal mixed tumor (carcinosarcoma).

Holmes BJ, Gown AM, Vang R, Ronnett BM, Yemelyanova A.

Int J Gynecol Pathol. 2014 Jul;33(4):425-31. doi: 10.1097/PGP.0b013e31829d7705.

PMID:
24901404
42.

Papillary cystadenoma of the epididymis and broad ligament: morphologic and immunohistochemical overlap with clear cell papillary renal cell carcinoma.

Cox R, Vang R, Epstein JI.

Am J Surg Pathol. 2014 May;38(5):713-8. doi: 10.1097/PAS.0000000000000152.

PMID:
24441657
43.

Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.

Ardighieri L, Zeppernick F, Hannibal CG, Vang R, Cope L, Junge J, Kjaer SK, Kurman RJ, Shih IeM.

J Pathol. 2014 Jan;232(1):16-22. doi: 10.1002/path.4293.

44.

Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma.

Nik NN, Vang R, Shih IeM, Kurman RJ.

Annu Rev Pathol. 2014;9:27-45. doi: 10.1146/annurev-pathol-020712-163949. Epub 2013 Aug 5. Review.

PMID:
23937438
45.

A subset of malignant phyllodes tumors harbors alterations in the Rb/p16 pathway.

Cimino-Mathews A, Hicks JL, Sharma R, Vang R, Illei PB, De Marzo A, Emens LA, Argani P.

Hum Pathol. 2013 Nov;44(11):2494-500. doi: 10.1016/j.humpath.2013.06.009. Epub 2013 Jul 31.

46.

Clinically occult tubal and ovarian high-grade serous carcinomas presenting in uterine samples: diagnostic pitfalls and clues to improve recognition of tumor origin.

Bagby C, Ronnett BM, Yemelyanova A, Maleki Z, Kuhn E, Vang R.

Int J Gynecol Pathol. 2013 Sep;32(5):433-43. doi: 10.1097/PGP.0b013e31826a6446.

PMID:
23896706
47.

Characteristics of hydatidiform moles: analysis of a prospective series with p57 immunohistochemistry and molecular genotyping.

Banet N, DeScipio C, Murphy KM, Beierl K, Adams E, Vang R, Ronnett BM.

Mod Pathol. 2014 Feb;27(2):238-54. doi: 10.1038/modpathol.2013.143. Epub 2013 Jul 26.

48.

Borderline atypical ductal hyperplasia/low-grade ductal carcinoma in situ on breast needle core biopsy should be managed conservatively.

Vandenbussche CJ, Khouri N, Sbaity E, Tsangaris TN, Vang R, Tatsas A, Cimino-Mathews A, Argani P.

Am J Surg Pathol. 2013 Jun;37(6):913-23. doi: 10.1097/PAS.0b013e31828ba25c.

49.

GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.

Cimino-Mathews A, Subhawong AP, Illei PB, Sharma R, Halushka MK, Vang R, Fetting JH, Park BH, Argani P.

Hum Pathol. 2013 Jul;44(7):1341-9. doi: 10.1016/j.humpath.2012.11.003. Epub 2013 Jan 31.

50.

Characterization of androgenetic/biparental mosaic/chimeric conceptions, including those with a molar component: morphology, p57 immnohistochemistry, molecular genotyping, and risk of persistent gestational trophoblastic disease.

Lewis GH, DeScipio C, Murphy KM, Haley L, Beierl K, Mosier S, Tandy S, Cohen DS, Lytwyn A, Elit L, Vang R, Ronnett BM.

Int J Gynecol Pathol. 2013 Mar;32(2):199-214. doi: 10.1097/PGP.0b013e3182630d8c.

PMID:
23370656

Supplemental Content

Support Center